## Pathophysiology and Clinical Significance of Coronary Atherosclerosis Atherosclerotic heart disease (ASHD) of the native coronary artery, classified under ICD-10 code I25.1, refers to the progressive narrowing and hardening of the arteries that supply oxygenated blood to the heart muscle. This condition is the primary cause of coronary artery disease (CAD) and remains a leading cause of morbidity and mortality worldwide. The pathophysiology is characterized by a multi-decade process beginning with endothelial injury. Risk factors such as chronic hypertension, dyslipidemia (specifically elevated LDL-C), diabetes mellitus, and cigarette smoking disrupt the vascular endothelium, leading to increased permeability. This allows for the infiltration of lipoproteins into the subendothelial space of the arterial wall. These lipoproteins undergo oxidative modification, which triggers an inflammatory response. Circulating monocytes are recruited to the site, where they transform into macrophages and ingest oxidized LDL, eventually becoming foam cells. The accumulation of these foam cells creates fatty streaks, the precursor to complex atherosclerotic plaques. ## Progression to Clinical Manifestations As the plaque matures, smooth muscle cells migrate to form a fibrous cap over a necrotic lipid core. The clinical presentation of I25.1 depends on the stability and extent of these plaques. Stable plaques lead to fixed narrowing of the vessel lumen, resulting in chronic stable angina—chest pain that occurs during exertion when oxygen demand exceeds supply. However, the most life-threatening aspect of ASHD is the potential for plaque rupture. Vulnerable plaques, often characterized by a thin fibrous cap and a large lipid-rich core, can rupture and expose thrombogenic material to the bloodstream, causing acute coronary syndromes such as unstable angina or myocardial infarction. Furthermore, chronic narrowing can lead to ischemic cardiomyopathy or congestive heart failure. ## Diagnostic and Therapeutic Approaches The diagnostic workup for I25.1 includes electrocardiography (ECG), which may show ST-segment changes or T-wave inversions, and stress testing (treadmill or pharmacological) to assess for inducible ischemia. Advanced imaging such as Coronary Computed Tomography Angiography (CCTA) allows for the non-invasive assessment of plaque burden and luminal stenosis. Invasive coronary angiography remains the gold standard for defining the anatomy and determining the necessity for revascularization. Management follows a comprehensive strategy of lifestyle modification, including the Mediterranean diet and regular aerobic exercise, combined with aggressive pharmacotherapy. Statins are used for plaque stabilization and lipid lowering, while antiplatelet agents like aspirin are standard to reduce the risk of thrombotic events. In cases of significant stenosis (typically greater than 70% in a major vessel), revascularization through Percutaneous Coronary Intervention (PCI) with drug-eluting stents or Coronary Artery Bypass Grafting (CABG) may be indicated to improve quality of life and prognosis. Long-term surveillance involves monitoring for the development of heart failure symptoms, periodic assessment of left ventricular function via echocardiography, and ensuring adherence to high-intensity medical therapy to prevent recurrent cardiovascular events.